Kenneth D. Westover, Ph.D. - Publications

Stanford University, Palo Alto, CA 
Transcription, Gene Regulation, Structural Biology

67 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Meyer C, McCoy M, Li L, Posner B, Westover KD. LIMS-Kinase provides sensitive and generalizable label-free measurement of kinase activity using mass spectrometry. Cell Reports. Physical Science. 4. PMID 38213501 DOI: 10.1016/j.xcrp.2023.101599  0.322
2023 Lu W, Liu Y, Gao Y, Geng Q, Gurbani D, Li L, Ficarro SB, Meyer CJ, Sinha D, You I, Tse J, He Z, Ji W, Che J, Kim AY, ... ... Westover KD, et al. Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1. Journal of Medicinal Chemistry. 66: 3356-3371. PMID 36826833 DOI: 10.1021/acs.jmedchem.2c01834  0.622
2022 Li Z, Ishida R, Liu Y, Wang J, Li Y, Gao Y, Jiang J, Che J, Sheltzer JM, Robers MB, Zhang T, Westover KD, Nabet B, Gray NS. Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. European Journal of Medicinal Chemistry. 238: 114433. PMID 35597007 DOI: 10.1016/j.ejmech.2022.114433  0.555
2022 Li L, Meyer C, Zhou ZW, Elmezayen A, Westover K. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. Journal of Molecular Biology. 167626. PMID 35595166 DOI: 10.1016/j.jmb.2022.167626  0.304
2021 Liu Y, Westover KD. Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay. Star Protocols. 2: 100587. PMID 34159321 DOI: 10.1016/j.xpro.2021.100587  0.341
2021 Park JM, Yang SW, Zhuang W, Bera AK, Liu Y, Gurbani D, von Hoyningen-Huene SJ, Sakurada SM, Gan H, Pruett-Miller SM, Westover KD, Potts MB. The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. Plos Biology. 19: e3001281. PMID 34077419 DOI: 10.1371/journal.pbio.3001281  0.401
2020 Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Correction to "Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6-benzo[]pyrimido[5,4-][1,4]diazepin-6-one Scaffold". Journal of Medicinal Chemistry. PMID 32790356 DOI: 10.1021/acs.jmedchem.0c01338  0.794
2020 Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chemical Biology. PMID 32755567 DOI: 10.1016/J.Chembiol.2020.07.011  0.774
2020 Strong AL, Spreadborough PJ, Pagani CA, Haskins RM, Dey D, Grimm PD, Kaneko K, Marini S, Huber AK, Hwang C, Westover K, Mishina Y, Bradley MJ, Levi B, Davis TA. Small molecule inhibition of non-canonical (TAK1-mediated) BMP signaling results in reduced chondrogenic ossification and heterotopic ossification in a rat model of blast-associated combat-related lower limb trauma. Bone. 115517. PMID 32622875 DOI: 10.1016/J.Bone.2020.115517  0.312
2020 Zhou ZW, Ambrogio C, Bera AK, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX, Janne PA, Westover KD. KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. Cancer Research. PMID 32605999 DOI: 10.1158/0008-5472.Can-20-0448  0.379
2020 Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Synthesis and structure activity relationships of DCLK1 kinase inhibitors based on a 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold. Journal of Medicinal Chemistry. PMID 32530623 DOI: 10.1021/Acs.Jmedchem.0C00596  0.807
2020 Gurbani D, Du G, Henning NJ, Rao S, Bera AK, Zhang T, Gray NS, Westover KD. Structure and Characterization of a Covalent Inhibitor of Src Kinase. Frontiers in Molecular Biosciences. 7: 81. PMID 32509799 DOI: 10.3389/Fmolb.2020.00081  0.823
2020 Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, ... ... Westover KD, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology. PMID 32251410 DOI: 10.1038/S41589-020-0506-0  0.802
2020 Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS. Birth Defects Research. PMID 32187889 DOI: 10.1002/Bdr2.1647  0.303
2020 Du G, Rao S, Gurbani D, Henning NJ, Jiang J, Che J, Yang A, Ficarro SB, Marto JA, Aguirre AJ, Sorger PK, Westover KD, Zhang T, Gray NS. Structure-based design of a potent and selective covalent inhibitor for SRC kinase that targets a p-Loop cysteine. Journal of Medicinal Chemistry. PMID 31935084 DOI: 10.1021/Acs.Jmedchem.9B01502  0.825
2020 Zhou Z, Ambrogio C, Bera A, Qing L, Cheng-Xiong X, Janne P, Westover K. Abstract IA03: KRAS Q61H preferentially signals through the MAPK pathway in non-small cell lung cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-Ia03  0.367
2020 Gurbani D, Westover K, Bera A. Abstract 4017: Biochemical and biophysical characterization of a covalent inhibitor of Src kinase Cancer Research. 80: 4017-4017. DOI: 10.1158/1538-7445.Am2020-4017  0.532
2019 Scarneo SA, Hughes PF, Yang KW, Carlson DA, Gurbani D, Westover KD, Haystead TAJ. A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. The Journal of Biological Chemistry. PMID 31914413 DOI: 10.1074/Jbc.Ra119.011857  0.507
2019 Zeng M, Xiong Y, Safaee N, Nowak RP, Donovan KA, Yuan CJ, Nabet B, Gero TW, Feru F, Li L, Gondi S, Ombelets LJ, Quan C, Jänne PA, Kostic M, ... ... Westover KD, et al. Exploring Targeted Degradation Strategy for Oncogenic KRAS. Cell Chemical Biology. PMID 31883964 DOI: 10.1016/J.Chembiol.2019.12.006  0.735
2019 Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD. Structural basis of the atypical activation mechanism of KRAS V14I. The Journal of Biological Chemistry. PMID 31341022 DOI: 10.1074/Jbc.Ra119.009131  0.304
2019 Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Li T, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, ... Westover KD, et al. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chemical Biology. PMID 30982749 DOI: 10.1016/J.Chembiol.2019.02.021  0.797
2019 Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, ... ... Westover KD, et al. Tissue-specific oncogenic activity of K-RasA146T. Cancer Discovery. PMID 30952657 DOI: 10.1158/2159-8290.Cd-18-1220  0.304
2019 Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Düster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology. PMID 30905681 DOI: 10.1016/J.Chembiol.2019.02.012  0.817
2019 Sung Hsieh HH, Agarwal S, Cholok DJ, Loder SJ, Kaneko K, Huber A, Chung MT, Ranganathan K, Habbouche J, Li J, Butts J, Reimer J, Kaura A, Drake J, Breuler C, ... ... Westover K, et al. Coordinating Tissue Regeneration through TGF-β Activated Kinase 1 (TAK1) In-activation and Re-activation. Stem Cells (Dayton, Ohio). PMID 30786091 DOI: 10.1002/Stem.2991  0.479
2018 Li Q, Wei X, Zhou ZW, Wang SN, Jin H, Chen KJ, Luo J, Westover KD, Wang JM, Wang D, Xu CX, Shan JL. GADD45α sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level. Cell Death & Disease. 9: 524. PMID 29743554 DOI: 10.1038/S41419-018-0452-X  0.317
2018 Ambrogio C, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, ... Westover KD, et al. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. PMID 29336889 DOI: 10.1016/J.Cell.2017.12.020  0.339
2017 Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. Jama Oncology. e173501. PMID 28973074 DOI: 10.1001/Jamaoncol.2017.3501  0.308
2017 Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, et al. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology. 24: 1029-1039.e7. PMID 28820959 DOI: 10.1016/J.Chembiol.2017.07.011  0.35
2017 Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, ... ... Westover KD, et al. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chemical Biology. PMID 28781124 DOI: 10.1016/J.Chembiol.2017.06.017  0.758
2017 Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure (London, England : 1993). PMID 28781083 DOI: 10.1016/J.Str.2017.07.003  0.641
2017 Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS. Covalent Guanosine Mimetic Inhibitors of G12C KRAS. Acs Medicinal Chemistry Letters. 8: 61-66. PMID 28105276 DOI: 10.1021/Acsmedchemlett.6B00373  0.69
2017 Ambrogio C, Kohler J, Zhou Z, Wang H, Paranal R, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter J, Chiarle R, Santamaría D, Westover K, Jänne P. P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1595  0.339
2016 Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, et al. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. PMID 28038940 DOI: 10.1016/J.Bmc.2016.11.034  0.825
2016 Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, et al. Structure-guided development of covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. PMID 28011204 DOI: 10.1016/J.Bmc.2016.11.035  0.819
2016 Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer W, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. The Journal of Biological Chemistry. PMID 27872191 DOI: 10.1074/Jbc.M116.750299  0.366
2016 Montalvo SK, Li L, Westover KD. Rationale for RAS mutation-tailored therapies. Future Oncology (London, England). PMID 27728979 DOI: 10.2217/Fon-2016-0363  0.305
2016 Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu MR, Shaul YD, ... ... Westover KD, et al. Corrigendum: A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nature Chemical Biology. 12: 656. PMID 27434767 DOI: 10.1038/Nchembio0816-656  0.673
2016 Hwang SY, Deng X, Byun S, Lee C, Lee SJ, Suh H, Zhang J, Kang Q, Zhang T, Westover KD, Mandinova A, Lee SW. Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling. Cell Reports. PMID 27320923 DOI: 10.1016/J.Celrep.2016.05.071  0.542
2016 Xia Y, Li Y, Westover KD, Sun J, Chen H, Zhang J, Fisher DE. Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin. Plos One. 11: e0155217. PMID 27152946 DOI: 10.1371/Journal.Pone.0155217  0.35
2016 Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD. Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiation Research. PMID 27135971 DOI: 10.1667/Rr14373.1  0.649
2016 Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu-Remaileh M, Shaul YD, ... ... Westover KD, et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nature Chemical Biology. PMID 27110680 DOI: 10.1038/Nchembio.2070  0.731
2016 Westover KD, Jänne PA, Gray NS. Progress on Covalent Inhibition of KRASG12C. Cancer Discovery. 6: 233-4. PMID 26951837 DOI: 10.1158/2159-8290.Cd-16-0092  0.541
2015 Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD. Structural dataset for the fast-exchanging KRAS G13D. Data in Brief. 5: 572-8. PMID 26958611 DOI: 10.1016/J.Dib.2015.10.001  0.317
2015 Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS. Development of small molecules targeting the pseudokinase Her3. Bioorganic & Medicinal Chemistry Letters. 25: 3382-9. PMID 26094118 DOI: 10.1016/J.Bmcl.2015.04.103  0.601
2015 Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Molecular Cancer Research : McR. PMID 26037647 DOI: 10.1158/1541-7786.Mcr-15-0203  0.348
2015 Westover KD, Iyengar P, Sharma AN, Timmerman R. SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 89: 87-93. PMID 26028304 DOI: 10.1016/J.Lungcan.2015.04.009  0.306
2015 Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, ... ... Westover KD, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). Journal of Medicinal Chemistry. 58: 183-96. PMID 25075558 DOI: 10.1021/Jm500480K  0.697
2015 Hunter JC, Gurbani D, Carrasco M, Manandhar A, Gondi S, Westover K. Abstract LB-031: Biochemical profiling of cancer-associated KRAS mutants: clues towards an understanding of differential clinical outcomes Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-031  0.384
2015 Udayakumar D, Pandita RK, Horikoshi N, Hunt CR, Liu Q, Wong K, Gray NS, Pandita TK, Westover KD. Abstract 2852: Torin2 suppresses ionizing radiation induced DNA damage repair Cancer Research. 75: 2852-2852. DOI: 10.1158/1538-7445.Am2015-2852  0.512
2015 Gurbani D, Tan L, Ficarro S, Hunter JC, Singer W, Vazquez FB, Xie T, Lim SM, Marto J, Gray NS, Westover KD. Abstract A178: Structure guided development of irreversible inhibitors for TAK1 Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A178  0.522
2014 Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS. Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology. 10: 1006-12. PMID 25326665 DOI: 10.1038/Nchembio.1658  0.581
2014 Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proceedings of the National Academy of Sciences of the United States of America. 111: 8895-900. PMID 24889603 DOI: 10.1073/Pnas.1404639111  0.494
2014 Laine AM, Westover KD, Choy H. Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. Seminars in Oncology. 41: 57-68. PMID 24565581 DOI: 10.1053/J.Seminoncol.2013.12.012  0.315
2014 Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angewandte Chemie (International Ed. in English). 53: 199-204. PMID 24259466 DOI: 10.1002/Anie.201307387  0.711
2014 Hunter J, Lim SM, Ficcarro SB, Choi HG, Gurbani D, Xie T, Marto JA, Gray NS, Westover K. Abstract PR07: Crystal structure of K-Ras G12C bound to an active site inhibitor Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Pr07  0.333
2013 Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research. 73: 2574-86. PMID 23436801 DOI: 10.1158/0008-5472.Can-12-1702  0.809
2012 Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, Lindquist S. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell. 150: 987-1001. PMID 22939624 DOI: 10.1016/J.Cell.2012.06.047  0.405
2012 Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. The Journal of Biological Chemistry. 287: 9742-52. PMID 22223645 DOI: 10.1074/Jbc.M111.304485  0.812
2009 Wang D, Bushnell DA, Huang X, Westover KD, Levitt M, Kornberg RD. Structural basis of transcription: backtracked RNA polymerase II at 3.4 angstrom resolution. Science (New York, N.Y.). 324: 1203-6. PMID 19478184 DOI: 10.1126/Science.1168729  0.514
2007 Wang D, Bushnell DA, Westover KD, Kaplan CD, Kornberg RD. Structural basis of RNA polymerase II substrate specificity and catalysis The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A656-C  0.509
2006 Wang D, Bushnell DA, Westover KD, Kaplan CD, Kornberg RD. Structural basis of transcription: role of the trigger loop in substrate specificity and catalysis. Cell. 127: 941-54. PMID 17129781 DOI: 10.1016/J.Cell.2006.11.023  0.523
2005 Boeger H, Bushnell DA, Davis R, Griesenbeck J, Lorch Y, Strattan JS, Westover KD, Kornberg RD. Structural basis of eukaryotic gene transcription. Febs Letters. 579: 899-903. PMID 15680971 DOI: 10.1016/J.Febslet.2004.11.027  0.695
2004 Batada NN, Westover KD, Bushnell DA, Levitt M, Kornberg RD. Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center. Proceedings of the National Academy of Sciences of the United States of America. 101: 17361-4. PMID 15574497 DOI: 10.1073/Pnas.0408168101  0.51
2004 Westover KD, Bushnell DA, Kornberg RD. Structural basis of transcription: nucleotide selection by rotation in the RNA polymerase II active center. Cell. 119: 481-9. PMID 15537538 DOI: 10.1016/J.Cell.2004.10.016  0.525
2004 Westover KD, Bushnell DA, Kornberg RD. Structural basis of transcription: separation of RNA from DNA by RNA polymerase II. Science (New York, N.Y.). 303: 1014-6. PMID 14963331 DOI: 10.1126/Science.1090839  0.498
2004 Bushnell DA, Westover KD, Davis RE, Kornberg RD. Structural basis of transcription: an RNA polymerase II-TFIIB cocrystal at 4.5 Angstroms. Science (New York, N.Y.). 303: 983-8. PMID 14963322 DOI: 10.1126/Science.1090838  0.511
2004 Westover KD, Bushnell DA, Kornberg RD. Structural Basis of Transcription Cell. 119: 1055. DOI: 10.1016/J.Cell.2004.12.014  0.474
Show low-probability matches.